Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions

Research output: Contribution to journalArticle

Abstract

Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.

Original languageEnglish (US)
Pages (from-to)907-917
Number of pages11
JournalFuture Oncology
Volume14
Issue number10
DOIs
StatePublished - Apr 1 2018

Fingerprint

Immunotherapy
Prostatic Neoplasms
Castration
Antigen-Presenting Cells
Patient Selection
Therapeutics
Biomarkers
Survival
sipuleucel-T
Direction compound
prostatic acid phosphatase

Keywords

  • biomarkers
  • cancer vaccine
  • castration-resistant prostate cancer
  • immunotherapy
  • prostate cancer
  • sipuleucel-T

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sipuleucel-T for the treatment of prostate cancer : Novel insights and future directions. / Handy, Catherine E.; Antonarakis, Emmanuel S.

In: Future Oncology, Vol. 14, No. 10, 01.04.2018, p. 907-917.

Research output: Contribution to journalArticle

@article{66245381761d44e7a731915737b16958,
title = "Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions",
abstract = "Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.",
keywords = "biomarkers, cancer vaccine, castration-resistant prostate cancer, immunotherapy, prostate cancer, sipuleucel-T",
author = "Handy, {Catherine E.} and Antonarakis, {Emmanuel S.}",
year = "2018",
month = "4",
day = "1",
doi = "10.2217/fon-2017-0531",
language = "English (US)",
volume = "14",
pages = "907--917",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - Sipuleucel-T for the treatment of prostate cancer

T2 - Novel insights and future directions

AU - Handy, Catherine E.

AU - Antonarakis, Emmanuel S.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.

AB - Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.

KW - biomarkers

KW - cancer vaccine

KW - castration-resistant prostate cancer

KW - immunotherapy

KW - prostate cancer

KW - sipuleucel-T

UR - http://www.scopus.com/inward/record.url?scp=85045473271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045473271&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0531

DO - 10.2217/fon-2017-0531

M3 - Article

C2 - 29260582

AN - SCOPUS:85045473271

VL - 14

SP - 907

EP - 917

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 10

ER -